Safety and Tolerability of Abelacimab compared to Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)

In by ECIR

Safety and Tolerability of Abelacimab compared to Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)

  • Hidden
  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria
  1. Male or Female ≥ 55 years of age
  2. History of AFib or AFlutter with planned indefinite use of anticoagulation
  3. CHA2DS2-VAsc Score ≥ 4 OR CHA2DS2-VAsc Score ≥ 3 with at least 1 of the following:
    • Planned concomitant use of aspirin (ASA) and/or P2Y12 inhibitor
    • CrCl ≤ 50 ml/min
Exclusion Criteria
  1. History of Mitral Stenosis
  2. History of Mechanical Heart Valve
  3. CrCl < 15 ml/min
  4. Intracranial or intraocular bleed within 3 months
  5. Plts < 70,000/mm3
  6. HgB <8 g/dL
  7. aPTT or PT >1.5 x ULN, if not on anticoagulant
Back to Current Studies